Cumberland Pharmaceuticals Business Update
Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The FDA has granted a rolling submission for the application, which will use data from the FIGHT DMD trial compared against natural history databases. The decision to file follows several regulatory meetings where the company addressed FDA questions regarding Phase 2 study results and efficacy endpoints.